Saizen is a drug owned by Emd Serono Inc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 27, 2016. Details of Saizen's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5898030 | hGH containing pharmaceutical compositions |
Apr, 2016
(8 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Saizen is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Saizen's family patents as well as insights into ongoing legal events on those patents.
Saizen's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Saizen's generic launch date based on the expiry of its last outstanding patent is estimated to be Apr 27, 2016 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Saizen Generics:
There are no approved generic versions for Saizen as of now.
Alternative Brands for Saizen
There are several other brand drugs using the same active ingredient (Somatropin Recombinant) as Saizen. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |||
|---|---|---|---|---|
| Emd Serono |
| |||
| Genentech |
| |||
| Novo Nordisk Inc |
| |||
| Pharmacia And Upjohn |
|
About Saizen
Saizen is a drug owned by Emd Serono Inc. Saizen uses Somatropin Recombinant as an active ingredient. Saizen was launched by Emd Serono in 2007.
Approval Date:
Saizen was approved by FDA for market use on 16 January, 2007.
Active Ingredient:
Saizen uses Somatropin Recombinant as the active ingredient. Check out other Drugs and Companies using Somatropin Recombinant ingredient
Dosage:
Saizen is available in injectable form for injection use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 5MG/VIAL | INJECTABLE | Prescription | INJECTION |
| 8.8MG/VIAL | INJECTABLE | Prescription | INJECTION |